SEC Form 4 · accession 0001493152-26-034812
Telomir Pharmaceuticals, Inc. · TELO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Paul Del Giudice
Director
Period of report
Apr 16, 2026
Accepted (ET)
Jul 27, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001971532
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Options (right to buy)F2,F1 | $1.34 | Apr 16, 2026 | A | 50,000 | A | — | Apr 16, 2036 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026.
- F2The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance.